Pascale Andre
18Patents
7h-index
35Co-inventors
62Inventor score
Filing activity: Dec 27, 2005 → Apr 8, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8119775B2 | Human anti-KIR antibodies | Chemistry; Metallurgy | 38 | Active |
| US9067997B2 | Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders | Emerging Cross-Sectional Technologies | 20 | Active |
| US8993319B2 | Monoclonal antibodies against NKG2A | Physics | 16 | Active |
| US10329348B2 | Treatment of cancers using anti-NKG2A agents | Chemistry; Metallurgy | 15 | Active |
| US10160810B2 | Monoclonal antibodies against NKG2A | Physics | 14 | Active |
| US8981065B2 | Human anti-KIR antibodies | Chemistry; Metallurgy | 13 | Active |
| US8637258B2 | Compositions and methods for regulating NK cell activity | Chemistry; Metallurgy | 9 | Active |
| US10711063B2 | Neutralization of inhibitory pathways in lymphocytes | Chemistry; Metallurgy | 7 | Active |
| US10676523B2 | Treatment regimens using anti-NKG2A antibodies | Chemistry; Metallurgy | 7 | Active |
| US10870700B2 | Neutralization of inhibitory pathways in lymphocytes | Chemistry; Metallurgy | 6 | Active |
| US8614307B2 | Nucleic acids encoding human anti-kir antibodies | Chemistry; Metallurgy | 6 | Active |
| US9789182B2 | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer | Chemistry; Metallurgy | 5 | Active |
| US11225519B2 | Treatment of cancers using anti-NKG2A agents | Chemistry; Metallurgy | 3 | Active |
| US11572410B2 | Neutralization of inhibitory pathways in lymphocytes | Chemistry; Metallurgy | 3 | Active |
| US9844593B2 | Methods for treatment of recurrent hematological malignancies | Emerging Cross-Sectional Technologies | 2 | Active |
| US10494433B2 | Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma | Chemistry; Metallurgy | 1 | Active |
| US10688180B2 | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer | Chemistry; Metallurgy | 1 | Active |
| US12037392B2 | Treatment regimens using anti-NKG2A antibodies | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.